Do platinum salts fit all triple negative breast cancers?

Cancer Treatment Reviews

Volumn 48, Issue , 2016, Pages 34-41

  Gerratana, L ^a,b   Fanotto, V ^a,b   Pelizzari, G ^a,b   Agostinetto, E ^b   Puglisi, F ^a,b  

^a UNIVERSITY OF UDINE   (Italy)

^b UNIVERSITY HOSPITAL OF UDINE   (Italy)

Author keywords

BRCAness; Carboplatin; Cisplatin; Triple negative breast cancer

Indexed keywords

ANTHRACYCLINE; BEVACIZUMAB; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; GEMCITABINE; INIPARIB; PACLITAXEL; PLATINUM; TAXANE DERIVATIVE; BRCA1 PROTEIN; BRCA1 PROTEIN, HUMAN; BRCA2 PROTEIN; BRCA2 PROTEIN, HUMAN; PLATINUM COMPLEX; RAD51 PROTEIN; RAD51 PROTEIN, HUMAN;

ANEMIA; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER PROGNOSIS; CANCER SURVIVAL; DIARRHEA; DISEASE FREE SURVIVAL; DNA CROSS LINKING; DNA DAMAGE; DRUG APPROVAL; DRUG EFFICACY; DRUG RESPONSE; EVENT FREE SURVIVAL; GENE MUTATION; GENOMIC INSTABILITY; GENOTYPE; GERMLINE MUTATION; HETEROZYGOSITY LOSS; HUMAN; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; NEXT GENERATION SEQUENCING; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; THROMBOCYTOPENIA; TREATMENT OUTCOME; TRIPLE NEGATIVE BREAST CANCER; TUMOR SUPPRESSOR GENE; CHEMISTRY; FEMALE; GENETICS;

BRCA1 PROTEIN; BRCA2 PROTEIN; FEMALE; GENES, BRCA1; GENES, BRCA2; HUMANS; ORGANOPLATINUM COMPOUNDS; RAD51 RECOMBINASE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TRIPLE NEGATIVE BREAST NEOPLASMS;

EID: 84975883831     PISSN: 03057372     EISSN: 15321967     Source Type: Journal    
DOI: 10.1016/j.ctrv.2016.06.004     Document Type: Review

References (87)

1. [1] Siegel, R.L., Miller, K.D., Jemal, A., Cancer statistics, 2016. CA Cancer J Clin 66 (2016), 7–30, 10.3322/caac.21332.
2. [2] Berry, D.A., Cronin, K.A., Plevritis, S.K., Fryback, D.G., Clarke, L., Zelen, M., et al. Effect of screening and adjuvant therapy on mortality from breast cancer. N Engl J Med 353 (2005), 1784–1792, 10.1056/NEJMoa050518.
3. [3] Giordano, S.H., Buzdar, A.U., Smith, T.L., Kau, S.-W., Yang, Y., Hortobagyi, G.N., Is breast cancer survival improving?. Cancer 100 (2004), 44–52, 10.1002/cncr.11859.
4. [4] La Vecchia, C., Bosetti, C., Lucchini, F., Bertuccio, P., Negri, E., Boyle, P., et al. Cancer mortality in Europe, 2000–2004, and an overview of trends since 1975. Ann Oncol 21 (2010), 1323–1360, 10.1093/annonc/mdp530.
5. [5] Park, S., Koo, J.S., Kim, M.S., Park, H.S., Lee, J.S., Lee, J.S., et al. Characteristics and outcomes according to molecular subtypes of breast cancer as classified by a panel of four biomarkers using immunohistochemistry. Breast 21 (2012), 50–57, 10.1016/j.breast.2011.07.008.
6. [6] Lam, S.W., Jimenez, C.R., Boven, E., Breast cancer classification by proteomic technologies: current state of knowledge. Cancer Treat Rev 40 (2014), 129–138, 10.1016/j.ctrv.2013.06.006.
7. [7] Sørlie, T., Perou, C.M., Tibshirani, R., Aas, T., Geisler, S., Johnsen, H., et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci 98 (2001), 10869–10874, 10.1073/pnas.191367098.
8. [8] Perou, C.M., Sørlie, T., Eisen, M.B., van de Rijn, M., Jeffrey, S.S., Rees, C.A., et al. Molecular portraits of human breast tumours. Nature 406 (2000), 747–752, 10.1038/35021093.
9. [9] Sorlie, T., Tibshirani, R., Parker, J., Hastie, T., Marron, J.S., Nobel, A., et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci 100 (2003), 8418–8423, 10.1073/pnas.0932692100.
10. [10] Dai, X., Li, T., Bai, Z., Yang, Y., Liu, X., Zhan, J., et al. Breast cancer intrinsic subtype classification, clinical use and future trends. Am J Cancer Res 5 (2015), 2929–2943.
11. [11] Bonotto, M., Gerratana, L., Iacono, D., Minisini, A.M., Rihawi, K., Fasola, G., Treatment of metastatic breast cancer in a real-world scenario: is progression-free survival with first line predictive of benefit from second and later lines?. Oncologist 20 (2015), 719–724, 10.1634/theoncologist.2015-0002.
12. [12] Gerratana, L., Fanotto, V., Bonotto, M., Bolzonello, S., Minisini, A.M., Fasola, G., et al. Pattern of metastasis and outcome in patients with breast cancer. Clin Exp Metastasis 32 (2015), 125–133, 10.1007/s10585-015-9697-2.
13. [13] Bonotto, M., Gerratana, L., Poletto, E., Driol, P., Giangreco, M., Russo, S., et al. Measures of outcome in metastatic breast cancer: insights from a real-world scenario. Oncologist 19 (2014), 608–615, 10.1634/theoncologist.2014-0002.
14. [14] Kennecke, H., Yerushalmi, R., Woods, R., Cheang, M.C.U., Voduc, D., Speers, C.H., et al. Metastatic behavior of breast cancer subtypes. J Clin Oncol 28 (2010), 3271–3277, 10.1200/JCO.2009.25.9820.
15. [15] Coates, A.S., Winer, E.P., Goldhirsch, A., Gelber, R.D., Gnant, M., Piccart-Gebhart, M., et al. Tailoring therapies – improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015. Ann Oncol 26 (2015), 1533–1546, 10.1093/annonc/mdv221.
16. [16] Sotiriou, C., Neo, S.-Y., McShane, L.M., Korn, E.L., Long, P.M., Jazaeri, A., et al. Breast cancer classification and prognosis based on gene expression profiles from a population-based study. Proc Natl Acad Sci 100 (2003), 10393–10398, 10.1073/pnas.1732912100.
17. [17] Bertucci, F., Finetti, P., Cervera, N., Esterni, B., Hermitte, F., Viens, P., et al. How basal are triple-negative breast cancers?. Int J Cancer 123 (2008), 236–240, 10.1002/ijc.23518.
18. [18] Nielsen, T.O., Hsu, F.D., Jensen, K., Cheang, M., Karaca, G., Hu, Z., et al. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res 10 (2004), 5367–5374, 10.1158/1078-0432.CCR-04-0220.
19. [19] Carey, L.A., Perou, C.M., Livasy, C.A., Dressler, L.G., Cowan, D., Conway, K., et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA 295 (2006), 2492–2502, 10.1001/jama.295.21.2492.
20. [20] Livasy, C.A., Perou, C.M., Karaca, G., Cowan, D.W., Maia, D., Jackson, S., et al. Identification of a basal-like subtype of breast ductal carcinoma in situ. Hum Pathol 38 (2007), 197–204, 10.1016/j.humpath.2006.08.017.
21. [21] Cheang, M.C.U., Voduc, D., Bajdik, C., Leung, S., McKinney, S., Chia, S.K., et al. Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype. Clin Cancer Res 14 (2008), 1368–1376, 10.1158/1078-0432.CCR-07-1658.
22. [22] Rouzier, R., Perou, C.M., Symmans, W.F., Ibrahim, N., Cristofanilli, M., Anderson, K., et al. Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin Cancer Res 11 (2005), 5678–5685, 10.1158/1078-0432.CCR-04-2421.
23. [23] Calza, S., Hall, P., Auer, G., Bjöhle, J., Klaar, S., Kronenwett, U., et al. Intrinsic molecular signature of breast cancer in a population-based cohort of 412 patients. Breast Cancer Res, 8, 2006, R34, 10.1186/bcr1517.
24. [24] Jumppanen, M., Gruvberger-Saal, S., Kauraniemi, P., Tanner, M., Bendahl, P.-O., Lundin, M., et al. Basal-like phenotype is not associated with patient survival in estrogen-receptor-negative breast cancers. Breast Cancer Res, 9, 2007, R16, 10.1186/bcr1649.
25. [25] Kreike, B., van Kouwenhove, M., Horlings, H., Weigelt, B., Peterse, H., Bartelink, H., et al. Gene expression profiling and histopathological characterization of triple-negative/basal-like breast carcinomas. Breast Cancer Res, 9, 2007, R65, 10.1186/bcr1771.
26. [26] Fan, C., Oh, D.S., Wessels, L., Weigelt, B., Nuyten, D.S.A., Nobel, A.B., et al. Concordance among gene-expression-based predictors for breast cancer. N Engl J Med 355 (2006), 560–569, 10.1056/NEJMoa052933.
27. [27] Carey, L.A., Dees, E.C., Sawyer, L., Gatti, L., Moore, D.T., Collichio, F., et al. The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res 13 (2007), 2329–2334, 10.1158/1078-0432.CCR-06-1109.
28. [28] Diaz, L.K., Cryns, V.L., Symmans, W.F., Sneige, N., Triple negative breast carcinoma and the basal phenotype: from expression profiling to clinical practice. Adv Anat Pathol 14 (2007), 419–430, 10.1097/PAP.0b013e3181594733.
29. [29] Hu, Z., Fan, C., Oh, D.S., Marron, J.S., He, X., Qaqish, B.F., et al. The molecular portraits of breast tumors are conserved across microarray platforms. BMC Genomics, 7, 2006, 96, 10.1186/1471-2164-7-96.
30. [30] Rakha, E.A., El-Sayed, M.E., Green, A.R., Lee, A.H.S., Robertson, J.F., Ellis, I.O., Prognostic markers in triple-negative breast cancer. Cancer 109 (2007), 25–32, 10.1002/cncr.22381.
31. [31] Tischkowitz, M., Brunet, J.-S., Bégin, L.R., Huntsman, D.G., Cheang, M.C.U., Akslen, L.A., et al. Use of immunohistochemical markers can refine prognosis in triple negative breast cancer. BMC Cancer, 7, 2007, 134, 10.1186/1471-2407-7-134.
32. [32] Lehmann, B.D., Bauer, J.A., Chen, X., Sanders, M.E., Chakravarthy, A.B., Shyr, Y., et al. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest 121 (2011), 2750–2767, 10.1172/JCI45014.
33. [33] Ring, B.Z., Hout, D.R., Morris, S.W., Lawrence, K., Schweitzer, B.L., Bailey, D.B., Generation of an algorithm based on minimal gene sets to clinically subtype triple negative breast cancer patients. BMC Cancer, 16, 2016, 10.1186/s12885-016-2198-0.
34. [34] Pegram, M.D., Lipton, A., Hayes, D.F., Weber, B.L., Baselga, J.M., Tripathy, D., et al. Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment. J Clin Oncol 16 (1998), 2659–2671.
35. [35] Wiggans, R.G., Woolley, P.V., Smythe, T., Hoth, D., Macdonald, J.S., Green, L., et al. Phase-II trial of tamoxifen in advanced breat cancer. Cancer Chemother Pharmacol 3 (1979), 45–48.
36. [36] Morris, G.J., Naidu, S., Topham, A.K., Guiles, F., Xu, Y., McCue, P., et al. Differences in breast carcinoma characteristics in newly diagnosed African-American and Caucasian patients: a single-institution compilation compared with the National Cancer Institute's Surveillance, Epidemiology, and End Results database. Cancer 110 (2007), 876–884, 10.1002/cncr.22836.
37. [37] Ho-Yen, C., Bowen, R.L., Jones, J.L., Characterization of basal-like breast cancer: an update. Diagn Histopathol 18 (2012), 104–111, 10.1016/j.mpdhp.2011.12.002.
38. [38] Hoeschele, J.D., In remembrance of Barnett Rosenberg. Dalton Trans 2009 (2003), 10648–10650, 10.1039/b918993a.
39. [39] Muggia, F.M., Bonetti, A., Hoeschele, J.D., Rozencweig, M., Howell, S.B., Platinum antitumor complexes: 50 years since Barnett Rosenberg's discovery. J Clin Oncol 33 (2015), 4219–4226, 10.1200/JCO.2015.60.7481.
40. [40] Sledge, G.W., Loehrer, P.J., Roth, B.J., Einhorn, L.H., Cisplatin as first-line therapy for metastatic breast cancer. J Clin Oncol 6 (1988), 1811–1814.
41. [41] Badve, S., Dabbs, D.J., Schnitt, S.J., Baehner, F.L., Decker, T., Eusebi, V., et al. Basal-like and triple-negative breast cancers: a critical review with an emphasis on the implications for pathologists and oncologists. Mod Pathol 24 (2011), 157–167, 10.1038/modpathol.2010.200.
42. [42] Huober, J., von Minckwitz, G., Denkert, C., Tesch, H., Weiss, E., Zahm, D.M., et al. Effect of neoadjuvant anthracycline-taxane-based chemotherapy in different biological breast cancer phenotypes: overall results from the GeparTrio study. Breast Cancer Res Treat 124 (2010), 133–140, 10.1007/s10549-010-1103-9.
43. [43] Turner, N.C., Ashworth, A., Biomarkers of PARP inhibitor sensitivity. Breast Cancer Res Treat 127 (2011), 283–286, 10.1007/s10549-011-1375-8.
44. [44] Silver, D.P., Richardson, A.L., Eklund, A.C., Wang, Z.C., Szallasi, Z., Li, Q., et al. Efficacy of neoadjuvant Cisplatin in triple-negative breast cancer. J Clin Oncol 28 (2010), 1145–1153, 10.1200/JCO.2009.22.4725.
45. [45] Lips, E.H., Mulder, L., Hannemann, J., Laddach, N., Vrancken Peeters, M.T.F.D., van de Vijver, M.J., et al. Indicators of homologous recombination deficiency in breast cancer and association with response to neoadjuvant chemotherapy. Ann Oncol 22 (2011), 870–876, 10.1093/annonc/mdq468.
46. [46] Scully, R., Chen, J., Ochs, R.L., Keegan, K., Hoekstra, M., Feunteun, J., et al. Dynamic changes of BRCA1 subnuclear location and phosphorylation state are initiated by DNA damage. Cell 90 (1997), 425–435.
47. [47] Shin, D.S., Chahwan, C., Huffman, J.L., Tainer, J.A., Structure and function of the double-strand break repair machinery. DNA Repair 3 (2004), 863–873, 10.1016/j.dnarep.2004.03.022.
48. [48] Davies, A.A., Masson, J.Y., McIlwraith, M.J., Stasiak, A.Z., Stasiak, A., Venkitaraman, A.R., et al. Role of BRCA2 in control of the RAD51 recombination and DNA repair protein. Mol Cell 7 (2001), 273–282.
49. [49] Topping, R.P., Wilkinson, J.C., Scarpinato, K.D., Mismatch repair protein deficiency compromises Cisplatin-induced apoptotic signaling. J Biol Chem 284 (2009), 14029–14039, 10.1074/jbc.M809303200.
50. [50] Paull, T.T., Cortez, D., Bowers, B., Elledge, S.J., Gellert, M., Direct DNA binding by Brca1. Proc Natl Acad Sci 98 (2001), 6086–6091, 10.1073/pnas.111125998.
51. [51] Quinn, J.E., Kennedy, R.D., Mullan, P.B., Gilmore, P.M., Carty, M., Johnston, P.G., et al. BRCA1 functions as a differential modulator of chemotherapy-induced apoptosis. Cancer Res 63 (2003), 6221–6228.
52. [52] Tan, D.S.P., Rothermundt, C., Thomas, K., Bancroft, E., Eeles, R., Shanley, S., et al. “BRCAness” syndrome in ovarian cancer: a case-control study describing the clinical features and outcome of patients with epithelial ovarian cancer associated with BRCA1 and BRCA2 mutations. J Clin Oncol 26 (2008), 5530–5536, 10.1200/JCO.2008.16.1703.
53. [53] Chu E, De Vita VT Jr. Physicians’ Cancer Chemotherapy Drug Manual 2015. Jones & Bartlett Learning; n.d.
54. [54] Ashworth, A., A synthetic lethal therapeutic approach: poly(ADP) ribose polymerase inhibitors for the treatment of cancers deficient in DNA double-strand break repair. J Clin Oncol 26 (2008), 3785–3790, 10.1200/JCO.2008.16.0812.
55. [55] Byrski, T., Gronwald, J., Huzarski, T., Grzybowska, E., Budryk, M., Stawicka, M., et al. Pathologic complete response rates in young women with BRCA1-positive breast cancers after neoadjuvant chemotherapy. J Clin Oncol 28 (2010), 375–379, 10.1200/JCO.2008.20.7019.
56. [56] Byrski, T., Dent, R., Blecharz, P., Foszczynska-Kloda, M., Gronwald, J., Huzarski, T., et al. Results of a phase II open-label, non-randomized trial of cisplatin chemotherapy in patients with BRCA1-positive metastatic breast cancer. Breast Cancer Res, 14, 2012, R110, 10.1186/bcr3231.
57. [57] Isakoff, S.J., Mayer, E.L., He, L., Traina, T.A., Carey, L.A., Krag, K.J., et al. TBCRC009: A multicenter phase ii clinical trial of platinum monotherapy with biomarker assessment in metastatic triple-negative breast cancer. J Clin Oncol 33 (2015), 1902–1909, 10.1200/JCO.2014.57.6660.
58. [58] Boulton, S.J., Cellular functions of the BRCA tumour-suppressor proteins. Biochem Soc Trans 34 (2006), 633–645, 10.1042/BST0340633.
59. [59] Catteau, A., Harris, W.H., Xu, C.F., Solomon, E., Methylation of the BRCA1 promoter region in sporadic breast and ovarian cancer: correlation with disease characteristics. Oncogene 18 (1999), 1957–1965, 10.1038/sj.onc.1202509.
60. [60] Esteller, M., Silva, J.M., Dominguez, G., Bonilla, F., Matias-Guiu, X., Lerma, E., et al. Promoter hypermethylation and BRCA1 inactivation in sporadic breast and ovarian tumors. J Natl Cancer Inst 92 (2000), 564–569.
61. [61] Campbell, P.J., Stephens, P.J., Pleasance, E.D., O'Meara, S., Li, H., Santarius, T., et al. Identification of somatically acquired rearrangements in cancer using genome-wide massively parallel paired-end sequencing. Nat Genet 40 (2008), 722–729, 10.1038/ng.128.
62. [62] Nik-Zainal, S., Van Loo, P., Wedge, D.C., Alexandrov, L.B., Greenman, C.D., Lau, K.W., et al. The life history of 21 breast cancers. Cell 149 (2012), 994–1007, 10.1016/j.cell.2012.04.023.
63. [63] Vollebergh, M.A., Lips, E.H., Nederlof, P.M., Wessels, L.F.A., Wesseling, J., Vd Vijver, M.J., et al. Genomic patterns resembling BRCA1- and BRCA2-mutated breast cancers predict benefit of intensified carboplatin-based chemotherapy. Breast Cancer Res, 16, 2014, R47, 10.1186/bcr3655.
64. [64] Timms, K.M., Abkevich, V., Hughes, E., Neff, C., Reid, J., Morris, B., Association of BRCA1/2defects with genomic scores predictive of DNA damage repair deficiency among breast cancer subtypes. Breast Cancer Res, 16, 2014, 10.1186/s13058-014-0475-x.
65. [65] Abkevich, V., Timms, K.M., Hennessy, B.T., Potter, J., Carey, M.S., Meyer, L.A., et al. Patterns of genomic loss of heterozygosity predict homologous recombination repair defects in epithelial ovarian cancer. Br J Cancer 107 (2012), 1776–1782, 10.1038/bjc.2012.451.
66. [66] Birkbak, N.J., Wang, Z.C., Kim, J.-Y., Eklund, A.C., Li, Q., Tian, R., et al. Telomeric allelic imbalance indicates defective DNA repair and sensitivity to DNA-damaging agents. Cancer Discov 2 (2012), 366–375, 10.1158/2159-8290.CD-11-0206.
67. [67] Popova, T., Manie, E., Rieunier, G., Caux-Moncoutier, V., Tirapo, C., Dubois, T., et al. Ploidy and large-scale genomic instability consistently Identify basal-like breast carcinomas with BRCA1/2 inactivation. Cancer Res 72 (2012), 5454–5462, 10.1158/0008-5472.CAN-12-1470.
68. [68] Watkins, J., Weekes, D., Shah, V., Gazinska, P., Joshi, S., Sidhu, B., et al. Genomic complexity profiling reveals that HORMAD1 overexpression contributes to homologous recombination deficiency in triple-negative breast cancers. Cancer Discov 5 (2015), 488–505, 10.1158/2159-8290.CD-14-1092.
69. [69] Alexandrov, L.B., Nik-Zainal, S., Wedge, D.C., Campbell, P.J., Stratton, M.R., Deciphering signatures of mutational processes operative in human cancer. Cell Rep 3 (2013), 246–259, 10.1016/j.celrep.2012.12.008.
70. [70] Nik-Zainal, S., Davies, H., Staaf, J., Ramakrishna, M., Glodzik, D., Zou, X., et al. Landscape of somatic mutations in 560 breast cancer whole-genome sequences. Nature, 2016, 10.1038/nature17676.
71. [71] Gronwald, J., Byrski, T., Huzarski, T., Dent, R., Bielicka, V., Zuziak, D., et al. Neoadjuvant therapy with cisplatin in BRCA1-positive breast cancer patients. ASCO Meet Abstr, 27, 2009, 502.
72. [72] Byrski, T., Huzarski, T., Dent, R., Gronwald, J., Zuziak, D., Cybulski, C., et al. Response to neoadjuvant therapy with cisplatin in BRCA1-positive breast cancer patients. Breast Cancer Res Treat 115 (2009), 359–363, 10.1007/s10549-008-0128-9.
73. [73] Alba, E., Chacon, J.I., Lluch, A., Anton, A., Estevez, L., Cirauqui, B., et al. A randomized phase II trial of platinum salts in basal-like breast cancer patients in the neoadjuvant setting. Results from the GEICAM/2006-03, multicenter study. Breast Cancer Res Treat 136 (2012), 487–493, 10.1007/s10549-012-2100-y.
74. [74] von Minckwitz, G., Schneeweiss, A., Loibl, S., Salat, C., Denkert, C., Rezai, M., et al. Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial. Lancet Oncol 15 (2014), 747–756, 10.1016/S1470-2045(14)70160-3.
75. [75] Benson, J.R., Jatoi, I., Highlights of the San Antonio Breast Cancer Symposium 2015: part 2. Future Oncol, 2016.
76. [76] Sikov, W.M., Berry, D.A., Perou, C.M., Singh, B., Cirrincione, C.T., Tolaney, S.M., et al. Impact of the Addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage II to III triple-negative breast cancer: CALGB 40603 (Alliance). J Clin Oncol 33 (2015), 13–21, 10.1200/JCO.2014.57.0572.
77. [77] Telli, M., Optimizing chemotherapy in triple-negative breast cancer: the role of platinum. Am Soc Clin Oncol Educ Book ASCO Am Soc Clin Oncol Meet, 2014, e37–42, 10.14694/EdBook_AM.2014.34.e37.
78. [78] Sikov, W., Berry, D., Perou, C., Singh, B., Cirrincione, C., Tolaney, S., et al. Event-free and overall survival following neoadjuvant weekly paclitaxel and dose-dense AC ± carboplatin and/or bevacizumab in triple-negative breast cancer: Outcomes from CALGB 40603. Cancer Res 76 (2016), S2–05, 10.1158/1538-7445.SABCS15-S2-05.
79. [79] Telli, M.L., Jensen, K.C., Vinayak, S., Kurian, A.W., Lipson, J.A., Flaherty, P.J., et al. Phase II study of gemcitabine, carboplatin, and iniparib as neoadjuvant therapy for triple-negative and BRCA1/2 mutation-associated breast cancer with assessment of a tumor-based measure of genomic instability: PrECOG 0105. J Clin Oncol 33 (2015), 1895–1901, 10.1200/JCO.2014.57.0085.
80. [80] Hofmann, D., Nitz, U., Gluz, O., Kates, R.E., Schinkoethe, T., Staib, P., et al. WSG ADAPT - adjuvant dynamic marker-adjusted personalized therapy trial optimizing risk assessment and therapy response prediction in early breast cancer: study protocol for a prospective, multi-center, controlled, non-blinded, randomized, investigator initiated phase II/III trial. Trials, 14, 2013, 261, 10.1186/1745-6215-14-261.
81. [81] Fontanella, C., Puglisi, F., Translational and clinical research highlights from the 38th San Antonio Breast Cancer Symposium. Future Oncol, 2016, 10.2217/fon-2016-0021.
82. [82] NCCN. NCCN Clinical Practice Guidelines in Oncology 2015.
83. [83] Senkus, E., Kyriakides, S., Ohno, S., Penault-Llorca, F., Poortmans, P., Rutgers, E., et al. Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 26 (2015), v8–30, 10.1093/annonc/mdv298.
84. [84] Sirohi, B., Arnedos, M., Popat, S., Ashley, S., Nerurkar, A., Walsh, G., et al. Platinum-based chemotherapy in triple-negative breast cancer. Ann Oncol 19 (2008), 1847–1852, 10.1093/annonc/mdn395.
85. [85] Staudacher, L., Cottu, P.H., Diéras, V., Vincent-Salomon, A., Guilhaume, M.N., Escalup, L., et al. Platinum-based chemotherapy in metastatic triple-negative breast cancer: the Institut Curie experience. Ann Oncol 22 (2011), 848–856, 10.1093/annonc/mdq461.
86. [86] Tutt, A., Ellis, P., Kilburn, L., Gilett, C., Pinder, S., Abraham, J., The TNT trial: A randomized phase III trial of carboplatin (C) compared with docetaxel (D) for patients with metastatic or recurrent locally advanced triple negative or BRCA1/2 breast cancer (CRUK/07/012). Cancer Res, 75, 2015, S3-01, 10.1158/1538-7445.SABCS14-S3-01.
87. [87] Rugo, H.S., Barry, W.T., Moreno-Aspitia, A., Lyss, A.P., Cirrincione, C., Leung, E., et al. Randomized phase III trial of paclitaxel once per week compared with nanoparticle albumin-bound nab-paclitaxel once per week or ixabepilone with bevacizumab as first-line chemotherapy for locally recurrent or metastatic breast cancer: CALGB 40502/NCCTG N063H (Alliance). J Clin Oncol 33 (2015), 2361–2369, 10.1200/JCO.2014.59.5298.